Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
961-980 of 1,738 trials

Relapsing Multiple Sclerosis: YTB323 Treatment Study

We are testing a new treatment called YTB323 for people with Relapsing Multiple Sclerosis who have had ongoing disease activity despite previous therapies. The study aims to assess its safety and effects on disease progression.

Relapsing Multiple Sclerosis1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesNeurology

INZ-701 for ENPP1 and ABCC6 Deficiency

We are studying the long-term safety of INZ-701 in patients with ENPP1 and ABCC6 deficiencies. This trial will help us understand how the drug works over time and its effects on certain blood markers.

Pseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/Phosphodiesterase 1 DeficiencyGeneralized Arterial Calcification of InfancyEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

Pemigatinib for Solid Tumors with FGFR Alterations

We are studying whether pemigatinib can help patients with recurrent or metastatic solid tumors that have a specific gene change. The trial aims to assess its effects on tumor growth and overall patient health.

Recurrent or Metastatic Solid Cancer with FGFR Alterations>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Multiple Myeloma: Venetoclax and Dexamethasone Study

We are investigating whether a combination of venetoclax and dexamethasone is effective for patients with relapsed and refractory multiple myeloma who have the translocation (11;14). This study aims to find out if this treatment can improve outcomes for these patients.

Multiple Myeloma>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesHematologyOncology

Pancreatic Cancer: CEB-01 Treatment Study

We are exploring a new treatment called CEB-01 for people with pancreatic cancer to see how safe it is and if it may help improve their condition.

Pancreatic Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Tuberculosis Treatment: Tedizolid vs. Linezolide

We are studying how well tedizolid works compared to linezolide in reducing tuberculosis bacteria in patients. This trial aims to find out which treatment may be more effective in the first days of therapy.

Multidrug-Resistant TuberculosisEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Advanced Solid Tumors: VERT-002 Study

We are studying a new anticancer drug, VERT-002, for patients with advanced solid tumors, including lung cancer with MET alterations. The trial aims to assess its safety and how well it may work.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Vitiligo Treatment: Methotrexate and UVB Phototherapy

We are studying whether combining methotrexate with UVB phototherapy helps adults with progressive vitiligo achieve better skin repigmentation. We will also assess the safety of this treatment and its impact on quality of life.

Vitiligo>2 yearsEfficacy phase (II)Investigational MedicinesDermatology

Facial Lines: IPN10200 Treatment Study

We are studying a new treatment for adults with moderate to severe upper facial lines to see if it improves their appearance compared to a placebo. The trial will assess both safety and effectiveness of the treatment.

Frown Lines6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

HIV Control: Pomalidomide Study

We are studying whether pomalidomide can help control HIV in people on treatment who take a break from their medication. The trial also examines its effects on the immune system and HIV persistence.

HIV-1 Infection3-6 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesInfectious DiseasesInternal Medicine

Squamous Cell Carcinoma of the Penis: Lymphadenectomy and Chemotherapy Study

We are studying a treatment combining surgery and chemotherapy for patients with inguinal lymph node metastases. The goal is to see if this approach improves survival and reduces the chance of cancer returning.

Penis Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Heart Attack Treatment: Cangrelor and Bivalirudin

We are studying a new combination of medications for patients with heart attacks in critical condition. The goal is to see if this treatment can prevent blood clots while keeping bleeding risks low.

Cardiogenic Shock>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Diffuse Large B-Cell Lymphoma: Axicabtagene Ciloleucel Study

We are studying a new treatment for patients with late relapse of diffuse large B-cell lymphoma to see if it improves their condition and quality of life. The trial also looks at the safety of this treatment.

Recurrent B-cell Non-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Microvillus Inclusion Disease: Crofelemer Study

We are testing the safety and effects of a new oral solution, Crofelemer, in children with Microvillus Inclusion Disease. The study aims to see if it can help reduce symptoms and improve health compared to a placebo.

Microvillous Inclusion Disease6-12 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteGastroenterologyPediatrics

Prostate Cancer Diagnosis: 18F-PSMA PET/MRI Study

We are testing a new imaging method to see how well it identifies clinically significant prostate cancer. This may help improve diagnosis accuracy for patients.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyUrology

Vulvar Squamous Cell Carcinoma: Pembrolizumab Study

We are studying whether Pembrolizumab can help shrink tumors in patients with vulvar squamous cell carcinoma before surgery. This trial also looks at how the treatment affects the immune system.

Vulvar Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

IgG4-Related Disease: Abatacept Treatment Study

We are investigating whether abatacept can help reduce the risk of disease recurrence in people with IgG4-related disease. This study aims to provide insights into a new treatment option for managing this condition.

IgG4-Related Disease>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineRheumatology

Generalized Myasthenia Gravis: DNTH103 Treatment Study

We are testing a new treatment called DNTH103 for adults with generalized myasthenia gravis. The study aims to evaluate its safety, tolerability, and effectiveness in managing symptoms.

Myasthenia Gravis3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Advanced Cancers with BRAF Mutations: Sorafenib and Trametinib Study

We are testing a combination of two medications for patients with advanced-stage cancers that have BRAF mutations. The goal is to find the best dose and understand how well this treatment works and its safety.

Advanced-Stage Cancer with BRAF Mutation>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Castration-Resistant Prostate Cancer: CC-1 Antibody Study

We are testing a new bispecific antibody for patients with castration-resistant prostate cancer. The study aims to evaluate its safety and how well it may work compared to existing treatments.

Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)OncologyUrology